A Prospective, observational, US-based study assessing outcomes, adverse events, treatment patterns, and quality of life in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma and treated with Valchlor
An observational study for patients diagnosed with mycosis fungoides cutaneous lymphoma and treated with Valchlor
Sponsor: Actelion Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAP5653
U.S. Govt. ID: NCT02296164
Contact: Larisa Geskin: 212-305-5293 / ljg2145@columbia.edu
Additional Study Information: The purpose of this study is to better understand the use of Valchlor in clinical practice. Other goals include describing the demographic and clinical characteristics of disease and health outcomes of patients treated with Valchlor. Participating in this study will not influence the usual care you receive from your doctor.
This study is closed
Investigator
Larisa Geskin, MD
Do You Qualify?
Have you been diagnosed with mycosis fungoides cutaneous and are being treated with Valchlor? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Larisa Geskin
ljg2145@columbia.edu
212-305-5293
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE